Serum neurofilament light chain is increased in hereditary spastic paraplegias

Content Provider	Semantic Scholar
Author	Wilke, Carlo Arthur Magnus Rattay, Tim W. Hengel, H. Zimmermann, M. Brockmann, Kathrin Schöls, Ludger Kuhle, Joerg Schüle, Rebecca Synofzik, Matthis
Copyright Year	2018
Abstract	Blood biomarkers are still largely missing in hereditary spastic paraplegias (HSPs). We here explored Neurofilament light chain (NfL) as a biomarker in HSP. Serum NfL was assessed in 96 HSP (63 genetically confirmed), 96 healthy control, and 33 ALS subjects by single molecule array (Simoa). Compared to controls, NfL was increased in HSP (P < 0.001), correlating with cross-sectional disease progression (ρ = 0.28). Levels were lower than in ALS (P < 0.001), allowing to differentiate HSP from ALS (AUC = 0.91). Serum NfL might serve as a biomarker in HSP indicating neuronal damage and, if confirmed longitudinally, disease progression. It might also support differentiating HSP from ALS.
Starting Page	876
Ending Page	882
Page Count	7
File Format	PDF HTM / HTML
PubMed reference number	30009206v1
Alternate Webpage(s)	https://doi.org/10.1002/acn3.583
DOI	10.1002/acn3.583
Journal	Annals of clinical and translational neurology
Volume Number	5
Language	English
Access Restriction	Open
Subject Keyword	Amyotrophic Lateral Sclerosis Biological Markers Heat shock proteins Nerve Degeneration Progressive Disease Spastic Paraplegia Spastic Paraplegia, Hereditary Spastic Quadriplegia
Content Type	Text
Resource Type	Article